Philip Morris International launches IQOS in Austin, targets 2030 market share

Mar.28
Philip Morris International launches IQOS in Austin, targets 2030 market share
Philip Morris International launches IQOS device in Austin, Texas, targeting 10% market share by 2030 in the US.

Key points:

  • Philip Morris International (PMI) officially launched its heated tobacco device, "IQOS," in Austin, Texas on March 27th, with a price of $60 and pods priced at $8.
  • PMI aims to occupy 10% of the cigarette and heated tobacco market share in the United States by 2030.
  • The IQOS has successfully undergone market testing in Austin and will now be promoted through various channels.

According to a report from Reuters on March 28, a senior executive at Philip Morris International (PMI) revealed that PMI officially launched its heated tobacco device "IQOS" in Austin, Texas on Thursday (March 27). Each device is priced at $60.

 

PMI hopes to capture a 10% market share in the cigarette and heated tobacco products market in the United States by 2030, and establish a large number of new user groups.

 

Previously in April, PMI revealed plans to launch "IQOS" in Austin, but this product has not yet been widely sold in the US market.

 

PMI announced that after successful market testing, "IQOS" will now be available to residents of Austin of legal smoking age, and there will be product demonstrations and trial events during the MotoGP Red Bull Grand Prix of the Americas in Austin. The IQOS device is priced at $60, with pods priced at $8 each.

 

Vice president and chief marketing officer, inhalables at PMI U.S, Francisca Rahardja, stated that in order to attract new consumers, PMI is selling IQOS at prices lower than in other markets in the United States. The product will be sold in pop-up shops and mobile stores, including one store that will be placed in downtown Austin for several months.

 

Rahardja pointed out that PMI has signed contracts with about 15 adult-only venues, such as bars, where mobile sales cars and "IQOS coaches" will be deployed to promote the product and educate consumers on its usage, targeting existing nicotine users.

 

PMI previously announced plans to launch IQOS in four cities across two states, but currently only the release in Austin has been confirmed.

 

The company is currently limited to launching the old version of the IQOS device in the United States, while waiting to obtain authorization to sell the latest version, the "IQOS ILUMA", in the US. The US FDA is reviewing Philip Morris International's (PMI) application for the "IQOS ILUMA". The FDA had previously approved PMI to sell the older version of the device, touting its ability to reduce smokers' exposure to harmful chemicals.

 

In 2024, a group of health advocates wrote a letter to the FDA opposing PMI's application related to IQOS.

 

Notice

1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.

2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.

3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.

Copyright

This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.

This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.

BAT H1 2025 Trading Update: Velo Volume Share Hits 29.7%, Vuse Revenue Falls 15%, glo Hilo Set for Broader Expansion
BAT H1 2025 Trading Update: Velo Volume Share Hits 29.7%, Vuse Revenue Falls 15%, glo Hilo Set for Broader Expansion
BAT’s H1 2025 revenue slightly beat expectations, with full-year growth forecast at 1–2%. Velo grew to 29.7% share in key markets; U.S. revenue surged. Glo Hilo doubled conversion in Serbia, set for wider rollout. Vuse revenue down ~15% amid illicit competition, but Vuse Ultra launch may aid H2 recovery.
Jun.03 by 2FIRSTS.ai
Philip Morris International invests in smoke-free electronic devices to reduce health risks.
Philip Morris International invests in smoke-free electronic devices to reduce health risks.
PMI invests in smoke-free electronic devices to reduce health risks caused by tobacco combustion, facing regulatory challenges and black market effects.
Jun.12 by 2FIRSTS.ai
Scoil Parent Company Winbond Technology Reports 90% Drop in Q1 2025 Net Profit, Revenue Falls 28% to 1.338 Billion Yuan
Scoil Parent Company Winbond Technology Reports 90% Drop in Q1 2025 Net Profit, Revenue Falls 28% to 1.338 Billion Yuan
The report reveals a 28.29% year-on-year decline in operating revenue to 1.338 billion yuan (RMB), while net profit attributable to shareholders of the listed company plummeted 90.43% to 15.1642 million yuan. Notably, selling expenses surged 103.08% year-on-year, which the company attributes to intensified global market expansion efforts to bolster its international strategic footprint.
Apr.27 by 2FIRSTS.ai
U.S. FDA Unveils AI Tool Elsa for Clinical Review, Internal Writing, and Data Processing
U.S. FDA Unveils AI Tool Elsa for Clinical Review, Internal Writing, and Data Processing
The U.S. Food and Drug Administration has officially launched Elsa, a generative AI tool designed to speed up clinical reviews, internal writing, and data processing tasks. After successful pilots across multiple departments, Elsa is now being rolled out agency-wide.
Jun.04 by 2FIRSTS.ai
BAT’s Vuse E-Cigarettes Accused of Misleading Carbon-Neutral Claims in U.S. Class Action Lawsuit
BAT’s Vuse E-Cigarettes Accused of Misleading Carbon-Neutral Claims in U.S. Class Action Lawsuit
British American Tobacco (BAT) and its subsidiary RJ Reynolds are facing a class action lawsuit in California over claims that their Vuse e-cigarette brand misled consumers with false carbon-neutral marketing. Vuse was promoted as “the world’s first carbon-neutral vape brand,” but many of the carbon credits used were found to have no real climate benefit. Consumers are seeking $5 million in damages.
Jun.05 by 2FIRSTS.ai
Malaysia's Kelantan State Has Banned E-Cigarettes for a Decade, but Illegal Sales Persist
Malaysia's Kelantan State Has Banned E-Cigarettes for a Decade, but Illegal Sales Persist
Malaysia’s Kelantan state has enforced a total ban on e-cigarettes since 2015. Despite the ban, illegal sales persist, with 16 shops shut down so far this year, compared to 67 in 2024.
May.15 by 2FIRSTS.ai